Role of renin-angiotensin system in gastric oncogenesis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 442-451

  Sugimoto, Mitsushige ^a   Yamaoka, Yoshio ^c   Shirai, Naohito ^b   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Gastroenterology   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Chemoprevention; Gastric cancer; Helicobacter pylori; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSINOGEN; CANDESARTAN; CAPTOPRIL; CHYMASE; ENALAPRIL; EPIDERMAL GROWTH FACTOR; FOSINOPRIL; GELATINASE A; GELATINASE B; GEMCITABINE; INTERLEUKIN 17; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN; VASCULOTROPIN;

ADVANCED CANCER; ALLELE; ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; ENZYME INHIBITION; GENOTYPE; HELICOBACTER INFECTION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LUNG METASTASIS; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CARCINOGENESIS; STOMACH MUCOSA; TUMOR GROWTH; TUMOR VOLUME;

EID: 84857282199     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06964.x     Document Type: Article

References (75)

1. El-Omar EM, Carrington M, Chow WH etal. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
2. El-Omar EM, Rabkin CS, Gammon MD etal. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003; 124: 1193-201.
3. Sugimoto M, Furuta T, Shirai N etal. Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2005; 22: 1033-40.
4. Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005; 128: 833-48.
5. Yamaoka Y, Ojo O, Fujimoto S etal. Helicobacter pylori outer membrane proteins and gastroduodenal disease. Gut 2006; 55: 775-81.
6. Ogura K, Maeda S, Nakao M etal. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbil. J. Exp. Med. 2000; 192: 1601-10.
7. Take S, Mizuno M, Ishiki K etal. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am. J. Gastroenterol. 2005; 100: 1037-42.
8. Fukase K, Kato M, Kikuchi S etal. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7.
9. Uemura N, Okamoto S, Yamamoto S etal. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345: 784-9.
10. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin. Pharmacol. Ther. 2006; 80: 41-50.
11. Sugimoto M, Furuta T, Shirai N etal. Effects of interleukin-10 gene polymorphism on the development of gastric cancer and peptic ulcer in Japanese subjects. J. Gastroenterol. Hepatol. 2007; 22: 1443-9.
12. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003; 35: 881-900.
13. Le Noble FA, Hekking JW, Van Straaten HW, Slaaf DW, Struyker Boudier HA. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol. 1991; 195: 305-6.
14. Muramatsu M, Yamada M, Takai S, Miyazaki M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensin-dependent pathway in hamster sponge granulomas. Br. J. Pharmacol. 2002; 137: 554-60.
15. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab. 2005; 16: 293-9.
16. Kondo K, Muramatsu M, Okamoto Y etal. Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J. Surg. Oncol. 2006; 93: 36-42.
17. Khaw KT, Barrett-Connor E. Systolic blood pressure and cancer mortality in an elderly population. Am. J. Epidemiol. 1984; 120: 550-8.
18. Urata H, Boehm KD, Philip A etal. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J. Clin. Invest. 1993; 91: 1269-81.
19. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C etal. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br. J. Cancer 2004; 90: 1059-68.
20. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell Biol. 2001; 116: 247-54.
21. Hallersund P, Elfvin A, Helander HF, Fandriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J. Renin Angiotensin Aldosterone Syst. 2011; 12: 54-64.
22. Sugimoto M, Ohno T, Graham DY, Yamaoka Y. Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci. 2009; 100: 2152-9.
23. Sugimoto M, Ohno T, Yamaoka Y. Gastric mucosal expression of angiotensin II type 1 and type 2 receptor mRNA in Helicobacter pylori-infected Mongolian gerbils. J. Gastroenterol. 2011; 46: 1177-86.
24. Hallersund P, Helander HF, Casselbrant A, Edebo A, Fandriks L, Elfvin A. Angiotensin II receptor expression and relation to Helicobacter pylori-infection in the stomach of the Mongolian gerbil. BMC Gastroenterol. 2010; 10: 3.
25. Yamaoka Y, Kita M, Kodama T, Sawai N, Kashima K, Imanishi J. Expression of cytokine mRNA in gastric mucosa with Helicobacter pylori infection. Scand. J. Gastroenterol. 1995; 30: 1153-9.
26. Yamaoka Y, Kodama T, Kashima K, Graham DY, Sepulveda AR. Variants of the 3′ region of the cagA gene in Helicobacter pylori isolates from patients with different H.pylori-associated diseases. J. Clin. Microbiol. 1998; 36: 2258-63.
27. Yamaoka Y, Kwon DH, Graham DY. A M(r) 34000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc. Natl Acad. Sci. U.S.A. 2000; 97: 7533-8.
28. Atherton JC, Cao P, Peek RM Jr, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J. Biol. Chem. 1995; 270: 17771-7.
29. Yamaoka Y, Kita M, Kodama T etal. Helicobacter pylori infection in mice: role of outer membrane proteins in colonization and inflammation. Gastroenterology 2002; 123: 1992-2004.
30. Franco AT, Johnston E, Krishna U etal. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res. 2008; 68: 379-87.
31. Rocken C, Lendeckel U, Dierkes J etal. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin. Cancer Res. 2005; 11: 2526-30.
32. Kinoshita J, Fushida S, Harada S etal. Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. Int. J. Oncol. 2009; 34: 1573-82.
33. Rocken C, Rohl FW, Diebler E etal. The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2007; 16: 1206-12.
34. Carl-McGrath S, Grantzdorffer I, Lendeckel U, Ebert MP, Rocken C. Angiotensin II-generating enzymes, angiotensin-converting enzyme (ACE) and mast cell chymase (CMA1), in gastric inflammation may be regulated by H.pylori and associated cytokines. Pathology 2009; 41: 419-27.
35. Shiomi S, Toriie A, Imamura S etal. IL-17 is involved in Helicobacter pylori-induced gastric inflammatory responses in a mouse model. Helicobacter 2008; 13: 518-24.
36. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin. Chim. Acta 1997; 265: 13-20.
37. Yasumatsu R, Nakashima T, Masuda M etal. Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J. Cancer Res. Clin. Oncol. 2004; 130: 567-73.
38. Noguchi R, Yoshiji H, Ikenaka Y etal. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol. Rep. 2009; 22: 355-60.
39. Yoshiji H, Noguchi R, Ikenaka Y etal. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. Curr. Med. Chem. 2007; 14: 2749-54.
40. Uemura H, Ishiguro H, Nakaigawa N etal. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol. Cancer Ther. 2003; 2: 1139-47.
41. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem. Biophys. Res. Commun. 2002; 294: 441-7.
42. Egami K, Murohara T, Shimada T etal. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003; 112: 67-75.
43. Miyajima A, Kosaka T, Asano T etal. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002; 62: 4176-9.
44. Arrieta O, Guevara P, Escobar E, Garcia-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br. J. Cancer 2005; 92: 1247-52.
45. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 1990; 86: 1343-6.
46. Koh WP, Yuan JM, Sun CL etal. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003; 63: 573-8.
47. Villard E, Tiret L, Visvikis S, Rakotovao R, Cambien F, Soubrier F. Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am. J. Hum. Genet. 1996; 58: 1268-78.
48. Gonzalez-Zuloeta Ladd AM, Vasquez AA, Sayed-Tabatabaei FA etal. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2143-6.
49. Ebert MP, Lendeckel U, Westphal S etal. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 2005; 14: 2987-9.
50. Medeiros R, Vasconcelos A, Costa S etal. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J. Pathol. 2004; 202: 330-5.
51. Shiotani A, Nishi R, Yamanaka Y etal. Renin-angiotensin system associated with risk of upper GI mucosal injury induced by low dose aspirin: renin angiotensin system genes' polymorphism. Dig. Dis. Sci. 2011; 56: 465-71.
52. Sugimoto M, Furuta T, Shirai N etal. Role of angiotensinogen gene polymorphism on Helicobacter pylori infection-related gastric cancer risk in Japanese. Carcinogenesis 2007; 28: 2036-40.
53. Goto Y, Ando T, Nishio K etal. The ACE gene polymorphism is associated with the incidence of gastric cancer among H.pylori seropositive subjects with atrophic gastritis. Asian Pac. J. Cancer Prev. 2005; 6: 464-7.
54. Sugimoto M, Furuta T, Shirai N, Ikuma M, Sugimura H, Hishida A. Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 1929-34.
55. Sugimoto M, Furuta T, Kodaira C etal. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J. Gastroenterol. 2008; 43: 751-61.
56. Loh M, Koh KX, Yeo BH etal. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur. J. Cancer 2009; 45: 2562-8.
57. Pfeufer A, Osterziel KJ, Urata H etal. Angiotensin-converting enzyme and heart chymase gene polymorphisms in hypertrophic cardiomyopathy. Am. J. Cardiol. 1996; 78: 362-4.
58. Urata H, Kinoshita A, Perez DM etal. Cloning of the gene and cDNA for human heart chymase. J. Biol. Chem. 1991; 266: 17173-9.
59. Inoue I, Nakajima T, Williams CS etal. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J. Clin. Invest. 1997; 99: 1786-97.
60. Yanai K, Nibu Y, Murakami K, Fukamizu A. A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene. J. Biol. Chem. 1996; 271: 15981-6.
61. Zhao YY, Zhou J, Narayanan CS, Cui Y, Kumar A. Role of C/A polymorphism at -20 on the expression of human angiotensinogen gene. Hypertension 1999; 33: 108-15.
62. Lever AF, Hole DJ, Gillis CR etal. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
63. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer 1999; 81: 761-6.
64. Williams RN, Parsons SL, Morris TM, Rowlands BJ, Watson SA. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur. J. Surg. Oncol. 2005; 31: 1042-50.
65. Wang L, Cai SR, Zhang CH etal. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. Chin. Med. J. 2008; 121: 2167-71.
66. Ramos-Nino ME, Maclean CD, Littenberg B. Association of angiotensin-converting enzyme inhibitor therapy and comorbidity in diabetes: results from the Vermont diabetes information system. BMC Endocr. Disord. 2008; 8: 17.
67. Lindholm LH, Anderson H, Ekbom T etal. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001; 358: 539-44.
68. Friis S, Sorensen HT, Mellemkjaer L etal. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-70.
69. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79years. Cancer 2003; 98: 1504-13.
70. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11: 627-36.
71. Nakai Y, Isayama H, Ijichi H etal. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 2010; 103: 1644-8.
72. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009; 135: 1429-35.
73. Uemura H, Hasumi H, Kawahara T etal. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int. J. Clin. Oncol. 2005; 10: 405-10.
74. Yoshiji H, Noguchi R, Toyohara M etal. Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol. 2009; 51: 315-21.
75. Muramatsu M, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J. Biol. Chem. 2000; 275: 5545-52.